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Abstract 
Few cases of premature infants with classi-
cal phenylketonuria (PKU) have been report-
ed. Treatment of these patients is challenging
due to the lack of a phenylalanine (Phe)-free
amino acid (AA) solution for parenteral nutri-
tion. A boy born at 27 weeks of gestation with
a weight of 1000 g was diagnosed with classi-
cal PKU on day 7 because of highly elevated
Phe level at newborn screening (2800 ʼmol/L).
Phe intake was suspended for 5 days and dur-
ing this time intravenous glucose and lipids as
well  as  small  amounts  of  Phe-free  formula
through nasogastric tube were given. Because
of insufficient weight gain attributable to defi-
ciency of essential AA, a Phe-reduced, BCAA-
enriched parenteral nutrition was added to sat-
isfy AA requirements without overloading in
Phe. Under this regimen, the boy started to
gain weight, Phe plasma levels progressively
reduced and normalized on day 19. At the age
of 40 months, the patient shows normal growth
parameters (height 25th percentile, weight 25-
50th percentile, head circumference 50th per-
centile) with a normal result for formally test-
ed psychomotor development (WPPSI-III). The
good outcome of the patient in spite of over 2
weeks of extremely high Phe concentrations
suggests  that  the  premature  brain  may  still
have enough plasticity to recover. Lacking a
Phe-free intravenous AA solution, successful
management of premature infants with PKU
depends  on  the  child’s  tolerance  of  enteral
nutrition.  Although  the  coincidence  of  PKU
and prematurity is rare, there is strong need
for the development of an appropriate Phe-free
amino  acid  solution  for  parenteral  nutrition
especially in case of gastro-intestinal compli-
cations of prematurity.
Introduction
Phenylketonuria (PKU; OMIM #261600) is an
autosomal recessive inherited defect of pheny-
lalanine hydroxylase (PAH, OMIM *612349, EC
1.14.16.1).  PAH  hydroxylates  phenylalanine
(Phe)  to  tyrosine  (Tyr)  in  the  presence  of
molecular  oxygen  and  catalytic  amounts  of
tetrahydrobiopterin (BH4), its essential cofac-
tor. The PAH gene is located on chromosome
12q24.1 and a high number of allelic variants
are known (www.biopku.org). PKU has an over-
all incidence in Europe and the USA of approxi-
mately  1:10,000-20,000  live  births.1 If  left
untreated, PKU results in elevated blood Phe
concentrations, low-to-normal blood Tyr concen-
trations and severe mental retardation with an
intelligence quotient (IQ) between 30 and 50.2
Reduced cerebral monoaminergic neurotrans-
mitters and reduced protein synthesis, caused
by impaired brain uptake of non-Phe large neu-
tral  amino  acids  in  the  presence  of  elevated
plasma Phe concentrations seem to be the main
pathophysiologic mechanism in PKU.3 The aim
of the treatment is to reduce the plasma Phe
concentration sufficiently to prevent neurologi-
cal  impairment.  Plasma  Phe  concentration
results from residual PAH activity, nutritional
Phe intake and growth rate. Depending on the
residual enzyme activity a more or less strict
reduction of dietary Phe intake is necessary to
achieve the desired plasma Phe concentration.
Complementation with a Phe-free amino acid
mixture is necessary in the majority of patients
to prevent protein deprivation and assure nor-
mal  growth.  Furthermore,  there  is  a  whole
range of low-protein food available to replace
protein-rich  dietary  components.2 In  classical
PKU this treatment is very restrictive and may
be associated with a risk of nutritional deficien-
cies. During intercurrent illness a high-energy
intake is necessary to counteract catabolism of
body protein leading to higher plasma Phe lev-
els. Sick children are often unable to take their
prescribed diet and need calory administration
via  naso-gastric  tube  or  intravenously.  The
treatment of premature PKU patients is very dif-
ficult as there are neither data about daily Phe
requirements nor specialized products for this
age  group.  Promotion  of  anabolism  (energy
requirement  for  growing  premature  infants:
110-130 kcal/kg/d) seems to be the best rational
to stabilize plasma Phe levels. National guide-
lines of several European countries for the man-
agement  of  PKU  recommend  that  treatment
should start as early as possible after birth and
should be monitored by Phe concentrations in
blood and clinical parameters.4-6It is known that
the developing brain is most sensitive to Phe
toxicity, In 2000 Burgard showed that the IQ
decreased by 0.5 standard deviation (approxi-
mately 7 points) for each 300 ʼmol/L rise in
blood Phe level. IQ scores appeared to stabilize
after the age of 10 years, even when Phe levels
exceeded  1200  ʼmol/L,  suggesting  that  diet
could  be  somewhat  relaxed  in  adolescence.7
Indeed, until recently, diet was stopped in many
countries after the age of 12 years. In a longitu-
dinal collaborative study Koch et al reported that
early-treated  adults  who  continued  diet  had
higher IQs than adults who discontinued diet at
an early age. In addition, adults with PKU who
continued diet performed at a level comparable
to genetic expectations as measured by their
parents’ IQ.8 High Phe levels are known to be
toxic  for  the  fetal  brain,  as  the  main  conse-
quences of maternal PKU are microcephaly and
mental retardation.9 However, no clear data are
available about the effect of high Phe in the
brain of premature babies and especially about
blood threshold Phe concentrations and/or dura-
tion of high Phe levels on clinical outcome of
these patients. There are only few reports of
preterm infants with PKU in the literature.10-13
Here we report on our experience in the man-
agement of a very preterm infant with classical
PKU.
Case Report
The  boy  is  the  first  child  of  non-consan-
guineous parents of Swiss origin. In the 26th
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week of gestation the mother was diagnosed to
have severe arterial hypertension and vaginal
bleedings. In the 27th week premature uterine
contractions  were  noticed.  The  mother
received  a  tocolysis,  but  due  to  a  placental
abruption the patient was born at 27 weeks of
gestation  after  antenatal  pulmonary  matura-
tion  with  corticosteroids  (2ﾥ12  mg  of
betamethasone intramuscularly with an inter-
val  of  24  h).  His  growth  parameters  were
appropriate with a birth weight of 1000 g (10th
percentile),  a  length  of  38  cm  (50-90th per-
centile) and a head circumference of 26 cm
(50-90th percentile). Neonatal adaptation was
good for his gestational age. Due to a wet-lung
syndrome he needed respiratory support with
continuous  positive  airway  pressure  (CPAP)
for a few days. He was diagnosed with classical
PKU  (genotype  c.1066-11G>A/c.1315+1G>A)
due  to  highly  elevated  phenylalanine  (Phe)
level at newborn screening (2800 ʼmol/L), per-
formed  on  day  4.  On  day  7,  when  newborn
screening results were available, plasma Phe
level was 3696 ʼmol/L. At this time the boy
received  little  amounts  of  enteral  nutrition
(Beba Alprem 16%, 60 ml/kg in 12 feeds) com-
pleted  with  a  parenteral  nutrition
(Vaminolact®, glucose and lipids) leading to a
protein intake of 3.9 g/kg/day (Figure 1 and
Table 1). The rather high protein intake for
weight and age probably explains the very high
plasma Phe level in this patient. Due to the
diagnosis of PKU Phe intake was arrested for 5
days (Figure 2 and Table 1). During this time
the  boy  received  intravenous  glucose  and
lipids as well as – due to the lack of a Phe-free
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Table 1. Nutritional intake during the first 35 days of life: Detailed information about total calorie intake (kcal/kg/d), parenteral calorie intake
(kcal/kg/d), enteral calorie intake (kcal/kg/d), total protein intake (g/kg/d), parenteral protein intake (g/kg/d), enteral protein intake, body weight
(kg), phenylalanine (Phe) intake (mg/d and mg/kg/d) and Phe and tyrosine (Tyr) concentrations in plasma (mol/L).
Day Body  Phe  Tyr Phe Phe Total protein Enteral protein  Parenteral  Total calorie  Parenteral  Enteral
weight Plasma Plasma intake intake intake intake   protein intake intake calorie  calorie 
(kg) (ʼmol/L) (ʼmol/L) (mg/d) (mg/kg/d) (g/kg/d) (g/kg/d)  (g/kg/d) (kcal/kg/d) intake intake
(kcal/kg/d) (kcal/kg/d)
11 - - 77 77 101 34 34 0
2 0.87 -- 136 156 1.8 0.1 1.7 49 44 5
3 0.87 -- 241 277 3.3 0.3 3 68 58 10
4 0.871 -- 247 284 3.4 0.4 3 81 67 14
5 0.834 2840 - 252 302 3.6 0.6 3 78 59 19
6 0.872 -- 259 297 3.8 0.8 3 93 66 27
7 0.915 3696 21 279 305 3.9 0.9 3 113 70 43
8 0.9 3403 67 00 0.9 0.9 0 90 45 45
9 0.9 2924 93 00 1.1 1.1 0 109 57 52
10 0.918 2993 132 00 1.3 1.3 0 110 49 61
11 0.9 2231 88 00 1.4 1.4 0 111 39 72
12 0.904 -- 0 02.2 2.2 0 120 39 81
13 0.944 1467 123 11 12 3.4 2.4 1 121 31 90
14 0.97 -- 3 33.1 2.8 0.3 125 22 103
15 0.98 830 48 33 3.4 3.1 0.3 136 22 114
16 0.967 -- 0 03.3 3.3 0 120 0 120
17 0.986 -- 0 03.3 3.3 0 120 0 120
18 1.009 34 58 32 32 3.4 3.4 0 123 0 123
19 1- -32 32 3.4 3.4 0 123 0 123
20 1.025 17 52 32 31 3.4 3.4 0 123 0 123
21 1.025 -- 102 100 3.9 3.9 0 137 0 137
22 1.03 -- 102 99 3.9 3.9 0 137 0 137
23 1.05 -- 102 97 3.9 3.9 0 137 0 137
24 1.11 -- 102 92 3.9 3.9 0 137 0 137
25 1.13 16 19 171 151 4.1 4.1 0 142 0 142
26 1.145 -- 171 149 4.1 4.1 0 142 0 142
27 1.185 -- 171 144 4.1 4.1 0 142 0 142
28 1.147 251 26 120 105 3.8 3.8 0 134 0 134
29 1.283 -- 120 94 3.3 3.3 0 117 0 117
30 1.335 -- 120 90 3.3 3.3 0 117 0 117
31 1.34 -- 120 90 3.3 3.3 0 117 0 117
32 1.32 -- 120 91 3.3 3.3 0 117 0 117
33 1.39 127 214 120 86 3.5 3.5 0 125 0 125
34 1.39 -- 120 86 3.5 3.5 0 125 0 125
35 1.4 -- 120 86 3.5 3.5 0 125 0 125[Pediatric Reports 2011; 3:e26] [page 105]
intravenous  amino  acid  solution  -  little
amounts of Phe-free formula (65-92 mL/kg/day
with a concentration of 14%, in 2-hourly feeds)
through a nasogastric tube. However, because
enteral feeding was poorly tolerated, the vol-
ume could not be increased rapidly. This led to
poor  weight  gain  and  an  only  very  slowly
declining  Phe  level  despite  Phe  deprivation
(Table 1). In order to promote anabolism and
thus induce protein synthesis and growth, a
parenteral nutrition solution rich in branched-
chain amino-acids, relatively poor in Phe and
unfortunately lacking tyrosine, commonly used
for  hepatic  insufficiency,  was  administered
(Aminosteril® Hepa 8%). Under this regimen
(Table  1),  Phe  plasma  levels  progressively
diminished and finally normalized on day 18
when intake of natural protein (infant formu-
la) was started. From day 19 to day 25 an oral
supplementation with leucine (4ﾥ25 mg) and
isoleucine (4ﾥ50 mg) was necessary to pre-
vent depletion of these essential amino acids.
The newborn lost a maximum of 16% of his
birth weight, which was attained again on day
18. Parenteral nutrition was stopped on day 16
when  the  baby  tolerated  complete  enteral
nutrition (only Phe-free formula at a concen-
tration of 15%). During several weeks we tried
to find the balance between the high caloric
and  protein  requirements,  the  limited  toler-
ance of liquid administration, and the risk of
necrotizing  enterocolitis  under  concentrated
enteral nutrition, all typical problems of pre-
mature children. 
The  patient  always  showed  appropriate
growth with height initially on the 10th per-
centile, going up to the 50th percentile at term
and finally reaching the 25th percentile at at 40
months. Weight was initially on the 50th per-
centile going up to the 97th percentile at a cor-
rected age of 3 to 6 months and finally stabiliz-
ing on the 50th percentile. Head circumference
was initially on the 90th percentile and slowly
came up to the 50th percentile by the corrected
age  of  18  months  stabilizing  there.  He  was
seen for neurodevelopmental follow-up at the
corrected  ages  of  6  months,  18  months,  24
months  and  at  the  chronological  age  of  40
months. Testing during the first 2 years was
done  with  the  Bayley  Scales  of  Infant
Development and with the French version of
the  WPPSI-III  (Wechsler  Preschool  and
Primary Scale of Intelligence, third edition) at
the age of 40 months. Standard neurological
examination  has  remained  normal.  Formal
developmental testing has shown scores in the
normal range, with some behavioral issues in
the last examination. He has a rather low Phe
tolerance (~200 mg/d) but keeps a good meta-
bolic  control  (average  plasma  Phe  level  277
ʼmol/L during the first two years) on diet.
Discussion
The  little  reported  experience  shows  that
the management of classical PKU in preterm
infants is not yet established. Adequate treat-
ment of these patients is complicated by two
problems: the lack of a Phe free amino acid
solution for parenteral infusion, and the lack of
reference values for safe Phe plasma concen-
trations related to gestational age. 
Cole et al. published the case of a premature
girl (second twin, less than 32 weeks of gesta-
tion) with a birth weight of 1480 g (Table 2).
She was diagnosed with PKU on day 12 with an
initial very high Phe level of 5670 ʼmol/L while
Case Report
Figure 2. Correlation between phenylalanine plasma levels and phenylalanine intake
during the first 35 days of life: Phenylalanine intake (mg/d) is given in light blue, total
protein intake (g/kg/d) in dark blue, calorie intake in green and plasma phenylalanine
levels in red triangles.
Figure 1. Evolution of parenteral and enteral nutrition during the first 35 days of life: the
body weight (kg) is indicated by the blue curve, total calorie intake (kcal/kg/d) by the
red curve. Proportions of parenteral (dark green) and oral (light green) nutrition are
demonstrated. Start and duration of specific products is marked above the graphic.[page 106] [Pediatric Reports 2011; 3:e26]
on parenteral nutrition for prematurity. At a
few months of age she had a relatively high
Phe tolerance of 97-128 mg/kg/d. Follow-up was
reported until the age of 16 months with nor-
mal  mental  and  motor  development.  The
authors draw attention to the fact that Phe-
free amino acid infusions might be necessary
for  preterm  infants  who  require  long-term
treatment.10 In 1985, Shortland et al. reported
on a girl born at 32 weeks of gestation with a
birth weight of 1560 g (Table 3). On day 13 she
had a plasma Phe level of 1879 ʼmol/L. She
had a Phe tolerance of less than 90 mg/kg/d
and needed between 270 and 290 mg/kg/d of
Tyr  to  achieve  a  normal  weight  gain.  The
authors  concluded  that  the  intake  of  Tyr
seemed  to  be  a  growth  limiting  factor.13
Randall et al. described a boy born at 30 weeks
of gestation with a birth weight of 2360 g and
an initial Phe level of 1926 ʼmol/L on day 19
(Table  3).  After  cessation  of  natural  protein
intake Phe plasma levels normalized rapidly,
but upon reintroduction of Phe he needed a
Phe intake as high as 100 mg/kg/d to maintain
plasma  Phe  levels  in  the  low  normal  range.
Elevated  Phe  requirements  normalized  at
term.  The  authors  concluded  that  preterm
infants with classical PKU may require higher
phenylalanine  intakes  in  order  to  meet
demands  of  growth.12 Hennermann  et  al.
described a premature girl (27 weeks of gesta-
tion, birth weight 1080 g) known to be het-
erozygous  for  classical  PKU  due  to  prenatal
diagnosis in a context of a positive family his-
tory (Table 3). On day 6 while on parenteral
nutrition with a Phe intake of 160 mg/kg/d, she
had a slightly elevated serum Phe level of 400
ʼmol/L that further rose to 515 ʼmol/L on day
8.  A  Phe-restricted  parenteral  and  enteral
nutrition  was  necessary  to  maintain  normal
serum Phe levels until the 42nd day of life. At
term  serum  Phe  levels  had  normalized.  The
authors  hypothesize  that  heterozygosity  for
PKU might be a risk factor for transient hyper-
phenylalaninemia  in  preterm  infants  and
could  be  explained  by  the  combination  of
immature  liver  function  and  the  genetically
determined reduced PAH activity.11
Our patient is the most premature reported
PKU patient so far, with the longest reported
neurodevelopmental follow-up. Despite a long
period (17 days) of highly elevated Phe levels
in the postnatal period he shows normal psy-
chomotor  development  without  neurological
impairment. Given the known toxicity of high
Phe blood levels on the developing brain14-16
and the irreversible brain damage that it can
cause in newborns when exposed to it even for
short  periods  of  time,2 the  outcome  of  our
patient suggests that the premature brain may
still  have  enough  plasticity  to  overcome  the
insult of at least 2 weeks of extremely high Phe
concentrations.  Furthermore,  it  is  possible
that brain damage has been limited by prompt
availability  of  sufficient  Tyr  and  other  large
neutral  amino-acids  through  the  parenteral
amino-acid solution, and the early supplemen-
tation  of  long-chain  polyunsaturated  fatty
acids (LCP) which are supposed to be involved
in  neural  and  cognitive  development  of
preterm infants.17
Our patient remained free of the frequent
complications of enteral feeding in premature-
ly born infants. The occurrence of one of these
complications would have made management
much more difficult. 
Conclusions
Even if the concurrence of significant pre-
maturity (in CH 1:100 for <32 weeks of gesta-
tion)  and  PKU  (in  CH  1:8000)  is  rare
(1:800,000), there is a clear need for appropri-
ate Phe-free parenteral nutrition in order to
guarantee optimal treatment in PKU patients
with gastro-intestinal complications of prema-
turity.  In  the  absence  of  a  specific  Phe-free
parenteral  nutrition,  amino  acid  solutions
used for hepatic disorders are more appropri-
ate than classical amino acid solutions for pre-
maturity,  because  of  their  high  content  of
essential  amino  acids  and  relatively  low
amount of aromatic amino acids. At present,
dietary  treatment  of  premature  infants  with
PKU depends on the baby’s tolerance of enter-
al nutrition. 
This  case  points  out  the  importance  of  a
timely diagnosis of PKU in premature babies,
as  these  patients  are  likely  to  receive  high
amounts of parenteral proteins during the first
weeks of life. Due to efficient logistics of new-
born screening in our country, the turnaround
time of results is limited to 2-3 days; therefore
diagnosis is usually made within the first week
of life. This may not be the case in other coun-
tries  where  preterm  PKU  babies  may  be
exposed for longer time to extremely high Phe
levels. 
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